Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Gyre Therapeutics (GYRE) Return on Invested Capital (2022 - 2025)

Historic Return on Invested Capital for Gyre Therapeutics (GYRE) over the last 8 years, with Q3 2025 value amounting to 0.06%.

  • Gyre Therapeutics' Return on Invested Capital rose 9300.0% to 0.06% in Q3 2025 from the same period last year, while for Sep 2025 it was 0.06%, marking a year-over-year increase of 9300.0%. This contributed to the annual value of 0.28% for FY2024, which is 29600.0% up from last year.
  • Per Gyre Therapeutics' latest filing, its Return on Invested Capital stood at 0.06% for Q3 2025, which was up 9300.0% from 0.05% recorded in Q2 2025.
  • Over the past 5 years, Gyre Therapeutics' Return on Invested Capital peaked at 12.25% during Q4 2023, and registered a low of 2.35% during Q1 2022.
  • For the 4-year period, Gyre Therapeutics' Return on Invested Capital averaged around 0.88%, with its median value being 0.06% (2022).
  • In the last 5 years, Gyre Therapeutics' Return on Invested Capital skyrocketed by 121800bps in 2023 and then crashed by -121300bps in 2024.
  • Over the past 4 years, Gyre Therapeutics' Return on Invested Capital (Quarter) stood at 0.07% in 2022, then skyrocketed by 18484bps to 12.25% in 2023, then crashed by -99bps to 0.12% in 2024, then tumbled by -47bps to 0.06% in 2025.
  • Its Return on Invested Capital stands at 0.06% for Q3 2025, versus 0.05% for Q2 2025 and 0.07% for Q1 2025.